
Source briefing
Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study
by Tianfang Shao, Mariana R. Neves, Molly Franke, Carole Mitnick, Jennifer Furin, Ted Cohen, Reza Yaesoubi Background Fluoroquinolones (FQs) are a cornerstone of most all-oral, shorter regimens endorsed by the World Health Organization for the treatment of rifampicin-resistant…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Trodelvy, sacituzumab govitecan, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 5, Status: Authorised
Read →

Source briefing
Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn
Read →
Source briefing
Jyothi Tirumalasetty on Asthma Inhalers and Climate Change
Jyothi Tirumalasetty, MD, a Stanford Medicine allergist, immunologist, and researcher, joins The Future of Medicine to explain an overlooked source of health care emissions: the propellants used in many common asthma inhalers.In this episode, Dr. Tirumalasetty explains how…
Read →
Source briefing
The longitudinal care cascade for hypertension in people with and without HIV in South Africa: A clinic-based observational study
by Siphamandla Bonga Gumede, Jennifer Manne-Goehler, Elizabeth Kelechi Oladimeji, Nicola Bulled, Alana T. Brennan, Samanta Tresha Lalla-Edward Background Hypertension (HTN) constitutes a major and growing public health challenge in South Africa, a setting where HIV prevalence also remains…
Read →
Source briefing
Protein mediators of chronic kidney disease in Type 2 diabetes: A mendelian randomization study
by Kevin Y. H. Liang, Thomas M. Zheng, Dandan Tan, Takayoshi Sasako, Yann Ilboudo, Yiheng Chen, Guillaume Butler-Laporte, Satoshi Yoshiji, J. Brent Richards Background Chronic kidney disease (CKD) occurs in 20–50% of the people living with Type 2…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 13, Status: Authorised
Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 13, Status: Authorised
Read →